Shots:

• Xbrane to initiate a new biosimilar development program annually and planning to generate positive operating cash flow monthly on the back of expected Xlucane net-income by late 2023/early 2024
• Xlucane (biosimilar- ranibizumab) referencing Lucentis is currently in the P-III trial with expected results in mid-2021- regulatory submissions are underway in the EU in Q3 & the US in Q4’21. If approved- Xlucane will be launched across the EU and the US
• The company has set the foundation for growth through establishing a new biotech lab at Campus Solna with a team of 50 professionals to take biosimilars from cell-line to approval and strengthen its high yield/low-cost platform technology

Ref: Xbrane | Image: Xbrane